Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imiquimod 5 % · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Imiquimod 5 % Cream | DRUG | - |
Inclusion Criteria: * Have a total of 4-10 actinic keratosis (AK) lesions located on either face or scalp * If female and of childbearing potential, have a negative urine pregnancy test at treatment initiation, and willing to use a medically acceptable method of contraception during the treatment p...
Imiquimod is a small molecule drug being developed by Viatris Inc. for the treatment of basal cell carcinoma and actinic keratosis. It is an investigational therapy that has been studied in clinical trials for these skin conditions.
Imiquimod is a small molecule drug that works through immune response modulation. It is being studied for its effectiveness in treating superficial basal cell carcinoma and actinic keratosis, particularly in organ transplant recipients.
Imiquimod is being developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The company is conducting clinical trials to evaluate the drug's effectiveness in treating certain skin conditions.
Imiquimod is in Phase 3 clinical development for basal cell carcinoma. It has completed Phase 3 trials, including a study evaluating the effectiveness of Imiquimod 5% cream in superficial basal cell carcinoma with 160 participants.
Imiquimod has been studied in several completed clinical trials. NCT00189241 was a Phase 3 trial in Germany for basal cell carcinoma with 160 participants. NCT00189267 was a Phase 2 trial for actinic keratosis in organ transplant recipients. NCT00189280 was a Phase 3 trial in France for basal cell carcinoma.
Imiquimod is also known as Aldara, as indicated by the clinical trial NCT00189280 titled 'Aldara for the Treatment of Large and/or Multiple sBCC'. This trial evaluated the drug for the treatment of superficial basal cell carcinoma.